Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 24 12 2018
revised: 02 01 2019
accepted: 02 01 2019
pubmed: 10 1 2019
medline: 14 6 2019
entrez: 10 1 2019
Statut: ppublish

Résumé

To determine the frequency and relevance of IgM, and IgA antibodies against myelin oligodendrocyte glycoprotein (MOG) in MOG-IgG-associated disease. Evaluation of IgM, and IgA MOG antibodies in serum of 120 patients with MOG-IgG (53 pediatric and 67 adults), and 114 patients with seronegative-MOG-IgG (35 children with first demyelinating syndrome, 20 adults with clinically isolated syndrome, and 59 adults with other diseases). Antibodies were examined by cell-based assays. IgM or IgA MOG antibodies were identified in 23/120 (19%) patients with MOG-IgG (13/53 [24.5%] pediatric, and 10/67 [15%] adult patients), and 2/114 (1.7%) patients with seronegative-MOG-IgG (2/35 [5.7%] pediatric patients). Of the 25 patients, 14 had IgA, 9 IgM, and 2 both antibodies. Fourteen of the 15 (93%) children with IgM (4), IgA (9), or both (2) had acute demyelinating encephalomyelitis (ADEM), and 7 of the 10 (70%) adults with IgM (5) or IgA (5) had optic neuritis at onset. At the last follow-up, the final diagnoses remained as ADEM in 14 (100%) children and optic neuritis in 6 (86%) adults. The outcome was not different between patients with or without additional classes of antibodies. Coexisting IgM and IgA antibodies occurs in 19% of children and adult patients with MOG-IgG-associated disease. The presence of these antibodies does not seem to play a relevant clinical role in the disorder.

Identifiants

pubmed: 30623863
pii: S2211-0348(19)30010-0
doi: 10.1016/j.msard.2019.01.007
pii:
doi:

Substances chimiques

Autoantibodies 0
Biomarkers 0
Immunoglobulin A 0
Immunoglobulin G 0
Immunoglobulin M 0
MOG protein, human 0
Myelin-Oligodendrocyte Glycoprotein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

230-234

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Marta Pedreño (M)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Maria Sepúlveda (M)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain.

Thais Armangué (T)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain; Pediatric Neuroimmunology Unit, Sant Joan de Deu Children's Hospital, University of Barcelona, Spain.

Lidia Sabater (L)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Eugenia Martínez-Hernandez (E)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain.

Georgina Arrambide (G)

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Yolanda Blanco (Y)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain.

Sara Llufriu (S)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain.

Elena H Martínez-Lapiscina (EH)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain.

Patricia Mulero (P)

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Nuria Sola-Valls (N)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain.

Raquel Ruiz-García (R)

Servicio de Inmunología, Centro de Diagnóstico Biomédico, Hospital Clinic of Barcelona, Barcelona, Spain.

Mar Tintoré (M)

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Josep Dalmau (J)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia, PA; Catalan Institution for research and Advanced Studies (ICREA), Barcelona, Spain.

Francesc Graus (F)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain.

Albert Saiz (A)

Neuroimmunology Program, Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unitat de Neuroimmunologia-Esclerosi múltiple, Servei de Neurología, Hospital Clinic, and Universitat de Barcelona, Barcelona, Spain. Electronic address: asaiz@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH